Source-grounded facts extracted from ELITE PHARMACEUTICALS INC /NV/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ELITE PHARMACEUTICALS INC /NV/ reported third quarter of fiscal year 2024 ended December 31, 2023 results: revenue $15.5 million.
“Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.”
ELITE PHARMACEUTICALS INC /NV/ reported the second quarter of fiscal year 2024 ended September 30, 2023 results: revenue $14.2 million, net income $14.9 million.
“Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.”
Carter J. Ward was appointed as chief financial officer, secretary, and treasurer at ELITE PHARMACEUTICALS INC /NV/.
“On September 5, 2023 (the “Effective Date”), Carter J. Ward was appointed as the Company’s chief financial officer, secretary, and treasurer.”
ELITE PHARMACEUTICALS INC /NV/ reported first quarter of fiscal year 2024 ended June 30, 2023 results: revenue $9.0 million, net income $1.1 million.
“Consolidated revenues for the three-month period ended June 30, 2023, were $9.0 million, an increase of $1.3 million or 16.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.6 million, an increase of $0.6 million or 60% from the comparable period of the prior year. Net income attributable to common shareholders was $1.1 million, an increase of $0.8 million or 267% from the comparable period of the prior year.”
ELITE PHARMACEUTICALS INC /NV/ dismissed Buchbinder Tunick & Company LLP as its auditor.
“The Audit Committee also dismissed Buchbinder Tunick & Company LLP (“Buchbinder”) as the Company’s independent registered public accounting firm, effective as of July 12, 2023.”
ELITE PHARMACEUTICALS INC /NV/ engaged Mazers USA LLP as its auditor.
“Company”) approved the appointment, effective July 11, 2023, of Mazers USA LLP (“Mazers”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending”
ELITE PHARMACEUTICALS INC /NV/ reported the fiscal year ended March 31, 2023 results: revenue $34.2 million, net income $3.6 million.
“Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year. Operating profits were $3.7 million, a decrease of $1.4 million from the comparable period of the prior year, and net income was $3.6 million.”
Robert Chen departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.”
Mark Pellegrino was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.”
Robert Chen resigned as Chief Financial Officer, Treasurer and Secretary at ELITE PHARMACEUTICALS INC /NV/.
“On February 25, 2023, Robert Chen notified Elite Pharmaceuticals, Inc. (the “Company”) of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary.”
ELITE PHARMACEUTICALS INC /NV/ reported the nine-month period ended December 31, 2022 results: revenue $25.5 million, net income $4.79 million.
“Consolidated revenues for the nine-month period ended December 31, 2022, were $25.5 million, an increase of $0.90 million or 4% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $4.1 million, a decrease of $0.10 million from the comparable period of the prior year, and net income was $4.79 million.”
ELITE PHARMACEUTICALS INC /NV/ reported the third quarter of fiscal year 2023 ended December 31, 2022 results: revenue $9.3 million, net income $2.96 million.
“Consolidated revenues for the three-month period ended December 31, 2022, were $9.3 million, an increase of $0.30 million or 3% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $2.0 million, an increase of $0.12 million from the prior year’s comparable period, and net income was $2.96 million.”
ELITE PHARMACEUTICALS INC /NV/ entered into Manufacturing and Supply Agreement with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).
“collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic”
ELITE PHARMACEUTICALS INC /NV/ entered into a asset purchase with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).
“On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”).”
ELITE PHARMACEUTICALS INC /NV/ terminated License, Supply and Distribution Agreement with Lannett Company, Inc. (effective 2022-11-09).
“On November 9, 2022, Elite Pharmaceuticals Inc. (“Elite”) and Lannett Company, Inc. (“Lannett”) jointly terminated the License, Supply and Distribution Agreement for Vigabatrin effective as of November 9, 2022.”
Kirko Kirkov was appointed as Chief Commercial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On September 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022.”
Marc Bregman departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“Effective as of May 16, 2022, Mr. Chen replaced Mr. Bregman as the Registrant’s Chief Financial Officer, and Mr. Bregman, who also served as the Registrant’s Secretary and Treasurer, ceased providing services to the Registrant in such capacities as of April 29, 2022.”
Robert Chen was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.
“On May 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Robert Chen to serve as the Registrants’ Chief Financial Officer, replacing Marc Bregman, who served as the Registrant’s Chief Financial Officer effective May 16, 2022.”
Marc Bregman resigned as Chief Financial Officer, Treasurer and Secretary at ELITE PHARMACEUTICALS INC /NV/.
“On April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. (the “Company”) of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.